

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report: November 10, 2016**  
**(Date of earliest event reported)**

---

**Arcadia Biosciences, Inc.**  
**(Exact name of registrant as specified in its charter)**

---

**Delaware**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**001-37383**  
**(Commission**  
**File Number)**

**81-0571538**  
**(I.R.S. Employer**  
**Identification No.)**

**202 Cousteau Place, Suite 105**  
**Davis, CA 95618**  
**(Address of principal executive offices, including zip code)**

**(530) 756-7077**  
**(Registrant's telephone number, including area code)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 10, 2016, Darby Shupp voluntarily resigned from the Board of Directors of Arcadia Biosciences, Inc. (the “Company”), effective immediately. There were no disagreements between Ms. Shupp and the Company or any officer or director of the Company that led to Ms. Shupp’s resignation. With the resignation, Ms. Shupp also resigned from her role as chairman of the Board of Directors and as chair of the Nominating and Governance Committee.

The Board intends to begin a search for an additional director. George Gosbee has been appointed as Interim Chairman of the Board, and has stepped down as chair of the Audit Committee. Kevin Comcowich has been appointed to serve as chair of the Audit Committee.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARCADIA BIOSCIENCES, INC.

Date: November 15, 2016

By: /s/ WENDY S. NEAL

Name: Wendy S. Neal

Title: Vice President, Chief Legal Officer & Secretary